Pyxis Oncology, an immuno-oncology company developing antibody drugs to restore activity to dysfunctional T cells, has appointed Ronald Herbst as its chief scientific officer. Herbst joins the Boston-based company from the AstraZeneca (NYSE: AZN) global biologics R&D arm, MedImmune, where he was vice president of research and development and head of oncology research.
Xconomy Insight · Special Report
Insights, wisdom, and inspiration on what it takes
From Our Partners · Special Report
Advice for funding and future transformational opportunities
From Our Editors · Special Report
Key indicators & expert insight from industry leaders
Xconomy
